Doxycycline as a potential partner of COVID-19 therapies

Malek, Alexandre; Granwehr, Bruno; Kontoyiannis, Dimitrios P.

doi:10.1016/j.idcr.2020.e00864

Cited by 95 publications

(97 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antiviral effects are secondary to transcriptional up-regulation of the intracellular zinc finger antiviral protein ZAP and repression of RNA translation. 13 In patients with moderate disease who are transplant recipients with multiple co-morbidities, out more than 2 years after the transplantation, leucopoenia and thrombocytopenia remain challenging scenarios to be managed without tocilizumab or antivirals, like remdesivir. [14][15][16] Another important consideration is the natural course of asymptomatic SARS-CoV-2 in a transplant recipient with multiple co morbidities (i.e.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

Choudhury¹,

Reddy²,

Venishetty³

et al. 2020

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

The severe acute respiratory syndrome corona virus-2 (referred to as SARS CoV2) pandemic had a great impact on public life in general as well as on populations with preexisting disease and co-morbidities. Liver transplant and immunosuppressant medication predisposes to more severe disease and is often associated with poor outcome. The clinical features, disease course, treatment and process of modulating the immunosuppression is challenging. Here, we describe the clinical presentation, treatment and outcomes in six liver transplant recipients. Out of those six patients, three had mild, one had moderate and one had severe COVID-19, and one was asymptomatic. The immunosuppression minimization or withdrawal was done based upon the clinical severity. Consideration of tocilizumab and/o convalescent plasma as well as antivirals i.e. remdesvir done in severe cases. The routine practice of prophylactic anticoagulation, consideration of repurposed drugs (i.e. teicoplanin and doxycycline), and watchful monitoring of asymptomatic recipients helped to achieve an uneventful recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

Choudhury¹,

Reddy²,

Venishetty³

et al. 2020

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

show abstract

“…Doxycycline could be an attractive option for the treatment of COVID-19 [26]. Therefore, the activity of doxycycline was assessed in vitro against a clinically isolated SARS-CoV-2 strain and was compared with the activity of chloroquine.…”

Section: Introductionmentioning

confidence: 99%

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Identifying effective antiviral drugs is urgently needed. An efficient approach to drug discovery is to evaluate whether existing approved drugs can be efficient against SARS-CoV-2. Doxycycline, which is a second-generation tetracycline with broad-spectrum antimicrobial, antimalarial and anti-inflammatory activities, showed in vitro activity on Vero E6 cells infected with a clinically isolated SARS-CoV-2 strain (IHUMI-3) with median effective concentration (EC50) of 4.5 ± 2.9 µM, compatible with oral uptake and intravenous administrations. Doxycycline interacted both on SARS-CoV-2 entry and in replication after virus entry. Besides its in vitro antiviral activity against SARS-CoV-2, doxycycline has anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines and could prevent co-infections and superinfections due to broad-spectrum antimicrobial activity. Therefore, doxycycline could be a potential partner of COVID-19 therapies. However, these results must be taken with caution regarding the potential use in SARS-CoV-2-infected patients: it is difficult to translate in vitro study results to actual clinical treatment in patients. In vivo evaluation in animal experimental models is required to confirm the antiviral effects of doxycycline on SARS-CoV-2 and more trials of high-risk patients with moderate to severe COVID-19 infections must be initiated.

show abstract

“…As mentioned by the same Author (Jomah et al, 2020), the side effect pro ile was many minimal. (Malek et al, 2020) have described both the anti-in lammatory and antiviral properties of doxycycline. These two properties, even weak, may be useful for countering such a killer disease.…”

Section: Drugs and Discussionmentioning

confidence: 99%

Partha’s covid 19 protocol – A preliminary pilot study in Indian patients

Parthasarathy¹,

Chandramohan²

2020

ijrps

View full text Add to dashboard Cite

Covid 19 is a pandemic affecting many countries with countless deaths and morbidities. There are many drugs, and immune-boosting nutraceuticals developed to tackle the same. There are no strict guidelines still yet described. We propose a guideline or a protocol termed as Partha’s protocol to counter every type of patient and contacts. In our early preliminary pilot study of 76 patients which included contacts, all were segregated into groups and received the drugs according to the protocol from Categories A to D. The basic strategies like social distancing and face masks continued. We had 19 positive cases and the rest as contacts. There was a need for minimal oxygen in two patients. Otherwise, there was no mortality. Among the contacts, there were only a few people (4 in number ) who turned symptomatic, and none turned swab positive. This protocol seems to look like polypharmacy, but all these drugs were being used for different indications safely for many years. Hence it's unlikely to encounter any significant side effects. We also advise taking antibody titre of IgG in the post-exposure group. If it turns out to be positive, we suggest avoiding repeated quarantine on recurrent exposures. We did not measure viral load as we considered early symptoms with exhaustion as a marker. To wait for evidence and then to tackle contacts and less sick patients may be detrimental to countries like India because of its vast population.

show abstract

Doxycycline as a potential partner of COVID-19 therapies

Cited by 95 publications

References 37 publications

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

Partha’s covid 19 protocol – A preliminary pilot study in Indian patients

Contact Info

Product

Resources

About